86
Participants
Start Date
June 30, 2010
Primary Completion Date
May 31, 2012
Study Completion Date
September 30, 2014
Ipilimumab and Fotemustine
Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
Medical Oncology and Immunotherapy-University Hospital of Siena, Siena
National Institute for Cancer Research, Genoa
Immunotherapy and Somatic Cell Therapy Unit, Scientific Institute of Romagna, Meldola
European Institute of Oncology, Milan
Melanoma Unit, San Raffaele Hospital, Milan
Surgical Oncology, National Cancer Institute, Milan
Medical Oncology and Innovative Therapy, National Cancer Institute, Naples
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Italian Network for Tumor Biotherapy
OTHER